John Alexander Kelly Acquires 2,113 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly purchased 2,113 shares of the stock in a transaction dated Friday, December 27th. The stock was acquired at an average cost of $4.75 per share, with a total value of $10,036.75. Following the transaction, the chief financial officer now directly owns 40,186 shares in the company, valued at approximately $190,883.50. This trade represents a 5.55 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL opened at $3.81 on Thursday. The firm has a 50 day moving average of $6.59 and a 200 day moving average of $8.51. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $29.23 million, a price-to-earnings ratio of 63.51 and a beta of 1.41. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $19.43.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Precision BioSciences stock. Geode Capital Management LLC boosted its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,974 shares of the company’s stock after purchasing an additional 19,088 shares during the quarter. Geode Capital Management LLC owned about 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.